We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Omega-3 PUFA Supplementation in NAFLD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00230113
Recruitment Status : Completed
First Posted : September 30, 2005
Last Update Posted : July 10, 2013
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.

Condition or disease Intervention/treatment Phase
Non-Alcoholic Fatty Liver Disease Dietary Supplement: Omega-3 fatty acid diet supplementation Dietary Supplement: safflower oil Phase 2

Detailed Description:

NAFLD is the most common liver disease in the United States and is also a common cause of abnormal liver tests in the United States. NAFLD includes mild as well as a more severe nonalcoholic fatty liver disease involving liver cell inflammation and damage, called Nonalcoholic Steatohepatitis (NASH). NAFLD is usually discovered because of abnormal liver tests or from a liver ultrasound or CT scan in persons with normal liver enzymes. Liver biopsy may show a mix of fat, inflammation and scarring in the liver. Patients with NAFLD do not drink large amounts of alcohol that can cause this type of liver damage. NAFLD is thought to be related to obesity and diabetes. Unfortunately, there is very little information about important features of NAFLD. These include biochemical, genetic and other features that may help to predict disease progression. The few known risk factors include high blood sugar and lipid levels. Patients with NAFLD often have resistance to the normal action of insulin, a hormone which is important for processing sugar and fat. Increased resistance to insulin leads to fat in the liver. Currently, there is no proven treatment for NAFLD. Several studies in animals suggest that diets containing high levels of omega-3 polyunsaturated fatty acids (PUFA) will decrease the amount of liver fat.

It has long been known that omega-3 fatty acids have several health benefits. For example, a diet rich in these fatty acids reduces the amount of certain fats ("triglycerides") in blood, and might improve the action of the important hormone insulin. Omega-3 fatty acids are contained in certain plant oils (such as canola oil and linseed oil) and marine fish (such as salmon). The purpose of this study is to determine the effect of dietary supplementation with ω-3 polyunsaturated vs monounsaturated fatty acids on intrahepatic fat content in patients with non-alcoholic fatty liver disease as determined by magnetic resonance spectroscopy

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Official Title: A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Diet Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease
Study Start Date : September 2005
Primary Completion Date : June 2010
Study Completion Date : June 2010

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1 Dietary Supplement: Omega-3 fatty acid diet supplementation
4 gm fish oil per day
Placebo Comparator: 2 Dietary Supplement: safflower oil
4 gm per day safflower oil

Outcome Measures

Primary Outcome Measures :
  1. Reduction of intrahepatic fat content as determined by magnetic resonance spectroscopy [ Time Frame: 2 month ]

Secondary Outcome Measures :
  1. Change in serum aminotransferase levels Change in lipid profile Change in levels of proinflammatory cytokines [ Time Frame: 2 month ]
  2. Change in insulin resistance determined by HOMA [ Time Frame: 2 month ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Acceptance into NASH CRN Database Study
  • Exclusion from or unwillingness to participate in the NASH CRN PIVENS Study
  • Histological diagnosis or imaging study suggesting NAFLD with at least 20% steatosis
  • Willingness to maintain study diet for duration of the study
  • At least 18 years of age
  • No contraindication for MRI scanning (i.e., pacemaker, shunts etc)

Exclusion Criteria:

  • Use of lipid lowering drugs (i.e., statins and fibrate drugs)
  • Use of insulin or thiazolidinediones
  • Use of drugs possibly associated with NAFLD (amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, or other known hepatotoxins) for more than 2 consecutive weeks in the 2 years prior to screening
  • Initiation of anti-diabetic drugs (insulin, biguanides, sulfonylureas, metformin, thiazolidinediones) in the 3 months prior to randomization
  • Initiation of anti-NASH drugs (thiazolidinediones, vitamin E, metformin, UDCA, SAM-e, betaine, milk thistle, gemfibrozil, anti-TNF therapies, probiotics) in the 3 months prior to randomization
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230113

United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Kris V Kowdley, MD University of Washington
More Information

Responsible Party: Kris Kowdley MD, Virginia Mason Medical Center
ClinicalTrials.gov Identifier: NCT00230113     History of Changes
Other Study ID Numbers: DK61728-S2
First Posted: September 30, 2005    Key Record Dates
Last Update Posted: July 10, 2013
Last Verified: July 2013

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Fatty Liver Disease
Omega-3 Fatty Acid
Fish oil

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases